Interpreting Tumor Markers

Documents to Request

• Serial tumor marker lab results with dates and reference ranges
• Pathology report confirming cancer diagnosis and receptor status
• Treatment timeline (chemotherapy cycles, surgery dates, radiation dates)
• Imaging reports from the same monitoring period
• Lab results for confounders (LFTs for AFP, renal function for β-hCG, lipase for CA 19-9)
• Prior marker baseline values (pre-treatment or pre-surgery)

Step 1: Confirm Validated Clinical Use for Each Marker

Key tumor markers and their ASCO/NCCN-validated clinical uses:

Reject any marker-clinical use combination not supported by ASCO, NCCN, or ESMO evidence-based guidelines. Document the guideline reference for each validated use.

Step 2: Analyze Marker Kinetics and Trends

Single values are rarely interpretable — trend analysis is mandatory.

Marker kinetic principles:

• Doubling time (DT): Calculate using at least 2 rising values: DT = (t × log2) / log(V2/V1). PSA doubling time <6 months after prostatectomy indicates aggressive recurrence.
• Half-life: Post-treatment decline should follow expected half-life: AFP half-life 5–7 days, β-hCG 24–36 hours, PSA 2.2 days post-prostatectomy. Failure to normalize per expected kinetics suggests residual disease.
• Nadir: The lowest post-treatment value. Rising above nadir by a clinically significant margin triggers further evaluation.
• Flare phenomenon: Some markers transiently increase in the first 2–4 weeks of effective treatment (PSA flare on enzalutamide/abiraterone, CA-125 flare on chemotherapy). Do not interpret a flare as progression.

Decision thresholds for action:

• PSA: biochemical recurrence = PSA ≥0.2 ng/mL and rising after prostatectomy; ≥2 ng/mL above nadir after radiation
• CEA: a rise >30% from nadir sustained on repeat testing warrants imaging
• CA-125: GCIG criteria for progression = doubling from nadir confirmed on repeat, or doubling from ULN if nadir not reached

Step 3: Assess Confounding Factors

Every elevated or unexpected marker result must be evaluated for non-malignant causes:

Document each confounder assessed and its status. If a confounder is present, its contribution to the elevation must be considered before attributing the result to malignancy.

Step 4: Generate Interpretive Report

Structure the interpretation as:

1. Marker and assay identification: Name, assay platform, laboratory reference range
2. Serial values table: All available values with dates, graphed if possible
3. Trend analysis: Rising, falling, stable, or fluctuating; kinetic calculations when applicable
4. Clinical context: Treatment administered, disease status, staging at last assessment
5. Confounder assessment: List assessed confounders with disposition
6. Interpretation: Consistent with response / stable disease / possible progression / indeterminate
7. Recommended action: Repeat in X weeks, correlate with imaging, no action needed, or escalate to oncologist

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is each marker being used only within its ASCO/NCCN-validated clinical context?
2. Are at least 3 serial data points used for trend analysis (not single-value interpretation)?
3. Have confounding non-malignant causes been systematically assessed?
4. Is the assay platform consistent across measurements, or has a platform change been flagged?
5. Does the interpretation align with concurrent imaging findings?

Quality Audit

• Marker validated for the specific cancer type and clinical use per ASCO/NCCN guidelines
• Assay platform and reference range documented for each measurement
• Minimum 3 data points used for trend analysis
• Kinetic calculations (doubling time, half-life) performed when clinically relevant
• Marker flare phenomenon considered during early treatment response
• Non-malignant confounders systematically assessed and documented
• Lewis antigen status noted when interpreting CA 19-9
• Anti-thyroglobulin antibody interference noted for thyroglobulin measurements
• Interpretation correlated with imaging and clinical assessment
• Recommended follow-up action specified with timeline
• Assay platform change between measurements flagged if present
• No use of markers for non-validated purposes (e.g., CA-125 for screening)
• Report structured for integration into medical record

Guidelines

• Never interpret a single tumor marker value in isolation — trends define clinical significance
• Always confirm the assay platform has not changed between serial measurements (different assays are not directly comparable)
• PSA values after prostatectomy should be undetectable (<0.1 ng/mL); any detectable PSA warrants further evaluation
• CA 19-9 is unreliable in Lewis antigen-negative patients — document Lewis antigen status when using CA 19-9
• Do not order tumor markers for screening in average-risk populations unless guideline-supported (only PSA has conditional screening support)
• Marker decline kinetics matter as much as absolute values — failure to follow expected half-life after treatment suggests residual disease
• CEA elevation from smoking does not negate the need for evaluation in colorectal cancer patients — the clinical context determines interpretation
• When markers and imaging are discordant, imaging takes precedence for treatment decisions, but discordance should prompt further investigation